ASX ANNOUNCEMENT
11 January 2016

BIONOMICS TO FEATURE AT 2016 SAN FRANCISCO BIOTECH SHOWCASE

Australian drug development company Bionomics Limited (ASX:BNO, OTCQX: BNOEF) advises that it will present a company update at Biotech Showcase™ 2016 on Wednesday 13 January, 2016 at 10.00am PST at the Parc 55 Hotel in San Francisco.

The three day event beginning today coincides with the 34th Annual JP Morgan Healthcare Conference and associated life sciences investment meetings. San Francisco in January each year brings together the largest global gathering of life sciences and healthcare professionals, investors and analysts, joining pharmaceutical company executives in extensive conferences and private meetings.

The Biotech Showcase™ is expected to attract over 1,700 attendees. Our presentation will highlight Bionomics’ strong clinical agenda in 2016. Most notable will be the:

- Start of our first cancer stem cell drug BNC101 trials in the first quarter
- Start of the Phase 2 BNC210 PTSD trial in the first half
- Positive data reported in September 2015 from the clinical trial of BNC210 providing first evidence of target engagement in the human brain
- Phase 2 results of BNC210 in anxiety sufferers is anticipated in the third quarter

Interactions across the week with investors and pharma companies will encompass the entire Bionomics pipeline of drug candidates with the clear objective of advancing partnering and clinical development.

This is a very important business development program of meetings and events for Bionomics. A copy of the presentation can be found on the Bionomics website www.bionomics.com.au

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics    Australia    US
Deborah Rathjen    Monsoon Communications    Stern IR, Inc.
Managing Director    Rudi Michelson    Beth Del Giacco
+618 83546101    +613 9620 3333    +1 212 362 1200
drathjen@bionomics.com.au    rudim@monsoon.com.au    beth@sternir.com
About Bionomics Limited
Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics’ lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 is expected to enter clinical trials in the first quarter of 2016. Bionomics has strategic partnerships with Merck & Co., Inc (known as MSD outside the United States and Canada) in pain and cognition.

www.bionomics.com.au

Factors Affecting Future Performance
This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics’ drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors’ drugs and drug candidates may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this announcement.